GENELUX CORPORATION Debt Conversion, Converted Instrument, Amount
GENELUX CORPORATION (GNLX) reported Debt Conversion, Converted Instrument, Amount of $1.86 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2025-03-28
- GENELUX CORPORATION debt conversion, converted instrument, amount for the quarter ending 2023-12-31 was $0.00.
- GENELUX CORPORATION debt conversion, converted instrument, amount for the quarter ending 2023-09-30 was $0.00.
- GENELUX CORPORATION debt conversion, converted instrument, amount for fiscal 2023 was $1.86M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $0.00 derived: sum of 2 quarters · filed 2025-03-28 | $1.86M 10-K · filed 2025-03-28 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.86M 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | $1.86M 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |